Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Dr Zeidan on the Evaluation of Immunotherapy and Other Novel Therapies in MDS

May 8th 2025

Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.

Dr Komrokji on the Expanded Indication for Luspatercept in Lower-Risk MDS

May 8th 2025

Rami Komrokji, MD, discusses several trials that supported the FDA approval of luspatercept for the treatment of patients with MDS with anemia.

Dr Monk the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

ADCs and PARP Inhibitors Are Among 2025’s Practice-Changing Agents in Ovarian Cancer

May 8th 2025

Deena M. Atieh Graham, MD, highlights the current treatment paradigm in ovarian cancer, particularly PARP inhibitors and new ADCs in the space.

Redefining Translational Research and China’s Impact on US Drug Development

May 7th 2025

In a 3-part series, Evan S. Wu, MD, PhD, will explore key issues surrounding the translatability of Chinese drug development data to a US population.

New ADCs Aim to Strengthen the HER2+ Breast Cancer Paradigm and Join T-DXd and T-DM1

May 6th 2025

The next-generation ADC ARX788 is under investigation in the phase 2 ACE-Breast-03 trial of patients with T-DXd–pretreated HER2-positive breast cancer.

Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small Cell Lung and Other Neuroendocrine Cancers

May 5th 2025

The DLL3- and CD3-targeted BiTE obrixtamig is being evaluated in patients with SCLC and other neuroendocrine cancers in the phase 2 DAREON-5 study.

Targeted Treatments Shift the Paradigm of Advanced BTC

May 5th 2025

During the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, an OncLive Peer Exchange® featured insights from expert investigators in the field of BTC.

Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC

May 2nd 2025

Alexis Chidi, MD, PhD, MSPH, details the evolution of surgical approaches in early-stage lung cancer, including wedge resections and segmentectomies.

Phase 3 Study of Capivasertib Plus Chemo/ADT in mCRPC to End After Recommendation From Data Monitoring Committee

May 1st 2025

The phase 3 CAPItello-280 trial of capivasertib plus docetaxel/ADT in metastatic castration-resistant prostate cancer is being discontinued.

Adjuvant Anlotinib Displays Efficacy in High-Grade Soft Tissue Sarcoma

May 1st 2025

Adjuvant anlotinib was safe and led to a DFS benefit vs surgery alone in completely resected high-grade soft tissue sarcoma.

Subgroup Analysis Shows No Key Differences Between High-Grade Recurrence, Cancer Progression Outcomes in BCG-Unresponsive NMIBC

April 30th 2025

Among 3 subgroups of patients with BCG-unresponsive NMIBC, no significant clinical differences were identified regarding rates of high-grade recurrence.

Neoadjuvant Botensilimab Plus Balstilimab Is Active, Safe Regardless of Mismatch Repair Status in Solid Tumors

April 30th 2025

Botensilimab and balstilimab proved active and safe as neoadjuvant therapy in patients with mismatch repair–deficient and –proficient solid tumors.

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

April 30th 2025

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

April 30th 2025

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma

April 29th 2025

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Sequencing Regorafenib After Fruquintinib Improves OS in mCRC

April 29th 2025

Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.

ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML

April 29th 2025

A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

April 29th 2025

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer

April 29th 2025

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.